Centrex (ASX:CXM) starts shipping with phosphate rock prices booming

Stuart Roberts Stuart Roberts, August 9, 2022

Centrex (ASX: CXM), developer of the Ardmore Phosphate Rock Project in northwestern Queensland, released a project update this morning.

The company is now shipping rock from Ardmore to Townsville at a rate of 10,000 tonnes per month and it intends to get this to 30,000 tonnes a month during the course of calendar 2023. It also expects that its first phosphate rock exports will be made next month.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

Phosphate rock price keeps on rising

Encouragingly, the price of phosphate rock as per the benchmark price, which is rock FOB North Africa as measured by the World Bank, has now reached US$320 a tonne, as against the mere US$125 a tonne at which Centrex did its Definitive Feasibility Study for what it is now calling ‘Ardmore 2.0’ where 800,000 tonnes per annum are produced .

That study placed a pre-tax NPV of $166m on Ardmore on a 10% discount rate. Centrex is currently doing Front End Engineering and Design on Ardmore 2.0 ahead of a Final Investment Decision (FID). In the meantime, the company is also contemplating an expansion of the original pilot plant, which it calls Ardmore Stage 1.5 and expects to be able to give an update on this in the near future.

 

Centrex price target of $0.21 at a minumum

Our minimum target price for CXM, one of our Stocks Down Under Concierge stocks, remains 21 cents.

 

Centrex

Centrex (ASX:CXM) price chart, log scale (Source: Tradingview)

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Nuix

Nuix (ASX:NXL) has quadrupled in 12 months! But is more growth to come?

Nuix (ASX:NXL) has been one of the most controversial companies on the ASX since it listed, but has it turned…

ASX Biotechs

Here are 3 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own…

buy the dip

When do you know it’s time to ‘buy the dip’? You could be catching a falling knife

‘Buy the dip’ – have you ever heard that term? It implies that when a company’s share price ‘dips’ or decreases,…